Target: CD119.
Clone: GIR 208.
Specificity: Anti-CD119 In Vivo Antibody - Ultra Low Endotoxin (GIR 208) recognizes Human IFN gamma R alpha.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: The IFN-gamma receptor is expressed at moderate levels on virtually every cell with the exception of erythrocytes.
Background: Interferon-gamma (IFN-gamma) exerts its biologic effects by interacting with a single high affinity receptor, IFN-gamma receptor. This receptor is present on almost all cell types except mature erythrocytes. The IFN-gamma receptor consists of two polypeptide chains alpha and beta and requires association of JAK1, JAK2 and Stat1 for IFN-gamma signal transduction. In signal transduction, IFN-gamma induces tyrosine phosphorylation of IFN-gamma receptor alpha (IFNGR1) leading to the formation of a docking site on the activated receptor for Stat1, which specifically activates IFN-gamma induced gene transcription. The IFN-gamma receptor is structurally related to the recently cloned IL-10 receptor. GIR 208 binds IFNGR1 and blocks binding of IFN-gamma to the receptor.
Immunogen: Human IFN-gamma R alpha, Purified from human placenta.
Concentration: 1.0 - 5.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.